Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Frontrunning: March 4 | ZeroHedge
- 0% Down, 100% Chance of Trouble | ZeroHedge
- This is Going to Push the US into Recession and Crush Stocks | ZeroHedge
- ISM Manufacturing Index: Slowest Growth in Thirteen Months | Financial Sense
- 3 Things - New Highs, Dollar Rally, Margin Debt | ZeroHedge
- The Chinese Buy Billboards Announcing The Renminbi As "The New World Currency" | ZeroHedge
- Poland Cuts Rates More Than Expected, 21st Central Bank "Policy Ease" Of The Year | ZeroHedge
The most relevant financial news and articles from the Internets
- Economists think the labor market had another great month in February | Business Insider
- BofA Merrill Lynch dealmaker Harry McMahon is resigning after 32 years | Business Insider
- Chicago mental health advocates claim Rahm Emanuel... | Business Insider
- Cavani seals PSG spot in French Cup semis | Business Insider
- Science says that charisma can be learned — here are 9 proven strategies | Business Insider
- Hillary Clinton won't take questions at event... | Business Insider
- Geico created a clever ad that rewards you in the best way possible when you... | Business Insider